'''Rindopepimut''' (CDX-110) is an injectable [[peptide]] [[cancer vaccine]]<ref name=Zussman2015/> which targets a mutant protein called [[Epidermal growth factor receptor|EGFRvIII]] present in about 25% to 30% of [[glioblastoma]] cases.<ref name=WSJ2015/>

The vaccine consists of the EGFRv3-specific peptide (a 13-[[amino acid]] mutant vIII [[epitope]]<ref name=Sciavolino2015/>) conjugated to the non-specific [[immunomodulator]] [[keyhole limpet hemocyanin]] (KLH).<ref>[http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=546970 rindopepimut definition]</ref>

The [[US FDA]] granted it [[Breakthrough Therapy]] Designation for glioblastoma in Feb 2015.<ref name=Sciavolino2015>[http://global.onclive.com/web-exclusives/FDA-Grants-Rindopepimut-Breakthrough-Designation-for-EGFRvIII-Positive-Glioblastoma FDA Grants Rindopepimut Breakthrough Designation for EGFRvIII-Positive Glioblastoma. Feb 2015]</ref>

==Clinical trials==

===Glioblastoma===
The phase II ACT III study reported encouraging results in June 2015.<ref name=Zussman2015>{{cite journal |url=http://journals.lww.com/neurosurgery/Fulltext/2015/06000/Outcomes_of_the_ACT_III_Study___Rindopepimut.7.aspx |title=Outcomes of the ACT III Study: Rindopepimut (CDX-110) Therapy for Glioblastoma. |doi=10.1227/01.neu.0000465855.63458.0c |author=Zussman |year=2015 |display-authors=etal}}</ref>

The ReACT clinical trial for glioblastoma reported encouraging results in 2015.<ref name=WSJ2015>[https://www.wsj.com/articles/celldex-vaccine-rindopepimut-cuts-death-risk-from-brain-cancer-study-shows-1448058339 Celldex Vaccine Rindopepimut Cuts Death Risk From Brain Cancer, Study Shows. WSJ Nov 2015]</ref>

In March 2016 the phase III ACT IV trial <ref>[https://clinicaltrials.gov/ct2/show/NCT01480479 Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma (ACT IV)]</ref> was terminated because it did not increase [[overall survival]].<ref>[http://global.onclive.com/web-exclusives/rindopepimut-misses-os-endpoint-in-phase-iii-glioblastoma-trial Rindopepimut Misses OS Endpoint in Phase III Glioblastoma Trial. March 2016]</ref>

==References==
{{reflist}}

==See also==
* [[glioblastoma multiforme]]

{{pharma-stub}}

[[Category:Vaccines]]
[[Category:Breakthrough therapy]]
[[Category:Experimental cancer drugs]]